Nonmyeloablative conditioning.
Showing 1 - 25 of 1,422
Sickle Cell Disease Trial in Saint Louis (drug, radiation, procedure)
Terminated
- Sickle Cell Disease
- Alemtuzumab
- +6 more
-
Saint Louis, MissouriWashington University School of Medicine
Jan 28, 2022
Hematologic Malignancies Trial in La Jolla (Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant)
Suspended
- Hematologic Malignancies
- Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
-
La Jolla, CaliforniaUCSD Medical Center
Jul 20, 2022
Malignant Tumor Trial in Los Angeles (biological, drug, other, radiation, procedure)
Active, not recruiting
- Malignant Neoplasm
- aldesleukin
- +7 more
-
Los Angeles, CaliforniaUniversity of California at Los Angeles (UCLA )
Dec 1, 2022
Sickle Cell Disease, Stem Cell Transplant Complications, Red Blood Cell Disorder Trial in Calgary (Alemtuzumab, Total Body
Recruiting
- Sickle Cell Disease
- +3 more
- Alemtuzumab
- +2 more
-
Calgary, Alberta, CanadaAlberta Children's Hospital
May 25, 2021
Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA), Severe Aplastic Anemia (SAA) Trial run by the NHLBI (Umbilical Cord
Completed
- Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA)
- Severe Aplastic Anemia (SAA)
- Umbilical Cord Blood
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 16, 2021
Metastatic Melanoma Trial in Los Angeles (F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells, non-myeloablative
Completed
- Metastatic Melanoma
- F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells
- non-myeloablative conditioning chemotherapy
-
Los Angeles, CaliforniaUniversity of California Los Angeles, David Geffen School of Med
Dec 3, 2021
Hematological Malignancies Trial in Belgium, Netherlands (Conditioning regimen: TBI + Fludarabine, Conditioning regimen:TLI (8
Completed
- Hematological Malignancies
- Conditioning regimen: TBI + Fludarabine
- Conditioning regimen:TLI (8 Gy) + ATG
-
Leuven, Flamish Brabant, Belgium
- +10 more
Nov 16, 2021
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma Trial in Seattle (Allogeneic Hematopoietic
Recruiting
- Acute Lymphoblastic Leukemia
- +16 more
- Allogeneic Hematopoietic Stem Cell Transplantation
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Dec 1, 2022
Multiple Myeloma, Refractory Multiple Myeloma Trial (procedure, drug, radiation)
Withdrawn
- Multiple Myeloma
- Refractory Multiple Myeloma
- nonmyeloablative allogeneic hematopoietic stem cell transplantation
- +7 more
- (no location specified)
Jan 4, 2023
Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, Leukemia, Myelocytic, Chronic Trial in Belgium (Mesenchymal stem
Terminated
- Leukemia, Myeloid, Acute
- +8 more
- Mesenchymal stem cells
- Isotonic solution
-
Edeghem, Antwerpen, Belgium
- +9 more
Aug 31, 2021
Leukemia, Lymphoma Trial in Houston (Rituximab, 111In Ibritumomab, Planar Scintigraphy Imaging)
Completed
- Leukemia
- Lymphoma
- Rituximab
- +11 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Apr 23, 2020
Sickle Cell Disease Trial run by the National Heart, Lung, and Blood Institute (NHLBI) (haploidentical stem cell transplant,
Recruiting
- Sickle Cell Disease
- haploidentical stem cell transplant
- +5 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 18, 2022
Lupus Erythematosus, Graft-versus-host Disease Trial in Baltimore (drug, radiation, biological)
Terminated
- Lupus Erythematosus
- Graft-versus-host Disease
- Cyclophosphamide
- +6 more
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sep 19, 2019
Mycosis Fungoides, Sezary Syndrome Trial run by the NHLBI (A matched peripheral donor stem cells, cyclosporine, fludarabine)
Completed
- Mycosis Fungoides
- Sezary Syndrome
- A matched peripheral donor stem cells
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Mar 2, 2020
Immunodeficiency Syndrome, Severe Aplastic Anemia, Genetic Disorder Trial in Nashville, Seattle (procedure, drug, other,
Terminated
- Immunodeficiency Syndrome
- +2 more
- Allogeneic Bone Marrow Transplantation
- +8 more
-
Nashville, Tennessee
- +2 more
Jan 6, 2021
Congenital Hemolytic Anemia, Sickle Cell Disease Trial run by the National Heart, Lung, and Blood Institute (NHLBI) (Peripheral
Recruiting
- Congenital Hemolytic Anemia
- Sickle Cell Disease
- Peripheral blood hematopoietic progenitor cell (PBPC) transplant
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 25, 2023
Sickle Cell Disease Trial in Canada, United States (Alemtuzumab intravenously, low dose total body irradiation, Sirolimus)
Recruiting
- Sickle Cell Disease
- Alemtuzumab intravenously, low dose total body irradiation, Sirolimus
-
Washington, District of Columbia
- +5 more
Mar 2, 2022
Hematopoietic Malignancy, Relapse/Recurrence, Hematopoietic Stem Cell Transplantation Trial in Suzhou (Umbilical Cord Blood
Recruiting
- Hematopoietic Malignancy
- +2 more
- Umbilical Cord Blood Transplantation
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow university
Nov 6, 2023
Severe Combined Immune Deficiency (SCID) Trial run by the National Institute of Allergy and Infectious Diseases (NIAID)
Enrolling by invitation
- Severe Combined Immune Deficiency (SCID)
- Sirolimus
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 24, 2022
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute
Completed
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +5 more
- Therapeutic Allogeneic Lymphocytes
-
Seattle, Washington
- +3 more
Jan 15, 2020
Chronic Granulomatous Disease Transplant Trial run by the NIAID (drug, radiation, biological)
Active, not recruiting
- Chronic Granulomatous Disease Transplant
- Alemtuzumab
- +5 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 21, 2023
Sickle Cell Disease, Thalassemia, Stem Cell Transplantation Trial run by the National Heart, Lung, and Blood Institute (NHLBI)
Recruiting
- Sickle Cell Disease
- +3 more
- Alemtuzumab
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Multiple Myeloma, High-Risk Cancer Trial in Montreal (Bortezomib following nonmyeloablative allogeneic transplant)
Active, not recruiting
- Multiple Myeloma
- High-Risk Cancer
- Bortezomib following nonmyeloablative allogeneic transplant
-
Montreal, Quebec, CanadaHôpital Maisonneuve-Rosemont
Aug 22, 2022
Sickle Cell Disease, Sickle Cell Disorder, Hemoglobinopathies Trial in Duarte (Cyclophosphamide, Pentostatin, Rabbit
Recruiting
- Sickle Cell Disease
- +4 more
- Cyclophosphamide
- +5 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jul 6, 2022
Samples and Data for National Marrow Donor Program Repository
Recruiting
- Bone Marrow Transplantation
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Nov 1, 2022